This Week in Cardiology

Obesity paradox studies and collider bias, the ISCHEMIA trial baseline findings, expanded indications for the MIitraClip, and an ACC preview are covered in this week’s podcast.

N of 1 hypertension trials, heart failure readmissions and HRRP, insulin, CTA vs functional stress testing, and the ongoing paclitaxel PAD controversy are discussed in this week’s podcast.

Lead extraction, AF triggers, cognitive decline and CV risk factors, low-value care, and secondary prevention in the real world are discussed in this week’s podcast.

Factor Xa reversal agent Andexa, PTSD, gender transition hormones and CVD, primary care physician shortage, and a commentary from a young interventional cardiologist are discussed this week.

The cost of cardiac care, statin adherence and mortality, syncope, ultra-processed food, and heart failure survival are discussed in this week's podcast.

Statins in the elderly, donor hearts and the opioid crisis, Impella, coronary calcium in exercisers, and the plateau in heart disease deaths are discussed in this week’s podcast.

New guidelines for atrial fibrillation, PFO closure for stroke prevention, fried chicken, skipping breakfast and e-cigarettes are discussed in this week’s podcast.

Aspirin for primary prevention, alcohol and Afib, high-sensitivity troponin, and women in interventional cardiology are discussed in this week’s podcast.

Burnout, aspiration thrombectomy, fish intake, insurance coverage, and the gout drug febuxostat are discussed in this week’s podcast.

Appropriate use criteria for imaging, HRRP efficacy, medical marijuana, radiation exposure in the cath lab, and hormone therapy are the topics discussed this week’s podcast.